Docomed.
Request a demo

Home  /  For Health Systems

Monitor your highest-risk patients, continuously.

For comorbid, high-risk patients, the gap between visits is where deterioration hides. Docomed closes it, turning a snapshot into a continuous signal, and moving activity out of the emergency pathway.

The case

Deterioration is predictable. Detection is the gap.

Your highest-risk patients, those with heart failure and COPD together, drive a disproportionate share of admissions and readmissions. Between appointments, no one is watching closely enough to catch decline early.

Docomed’s remote monitoring gives those patients frequent, diagnostic-quality assessment at home, so deterioration is caught while it can still be managed in the community.

  • Fewer avoidable admissions. Catch decompensation before it becomes an emergency.
  • Lower readmission exposure. Reduce the 30-day returns that carry financial penalties.
  • Protected capacity. Move activity out of A&E, outpatients and unplanned contacts.
  • Better quality metrics. Stronger performance on the measures that drive value-based contracts.

Proven outcomes

What continuous monitoring delivered.

Across ~6,000 high-risk patients in the NHS Frimley ICS remote-monitoring programme:

−53.7%
hospital admissions
−38.6%
A&E attendances
−36.3%
999 emergency calls
−26.7%
outpatient appointments

See the full evidence

The Triple-P value

Value across payer, provider and patient.

Payer

Fewer admissions

50%+ fewer

hospital admissions through early detection, spend moved from crisis to prevention.

Provider

Reduced burden

Up to 70% less

length of stay, with a 50%+ reduction in readmissions, capacity returned to the system.

Patient

Caught earlier

Days, not events

early detection of cardiac and respiratory deterioration, and more time lived at home.

How we partner

Start with evidence, scale with confidence.

Docomed launches through health systems: a focused pilot on a high-risk cohort generates outcomes and savings data on your own population, which becomes the basis for wider rollout. Health systems generate the evidence, and that evidence carries the model to scale.

The commercial model

Infrastructure, not a per-patient device.

CarePortal® / Artemis-Pro™ should not be viewed as a device sold on a per-patient basis, but as a healthcare infrastructure platform, capable of serving entire physician practices and specialist clinics, and providing access to very large patient populations from a comparatively small installed base.

Installed base
A small footprint
A comparatively small number of platform units deployed.
Deployed across
Practices & clinics
Entire physician practices and specialist clinics, not single patients.
Reaching
Large populations
Access to very large patient populations from that same base.

Model the impact on your population.

We’ll help you scope a pilot on a high-risk cohort and project the effect on admissions and capacity.

I'm a clinician I'm a health system